APPLIED GENETIC TECHNOLOGIES (AGTC) Stock Price, Forecast & Analysis
USA - NASDAQ:AGTC - US03820J1007 - Common Stock
AGTC Key Statistics, Chart & Performance
The current stock price of AGTC is 0.3936 USD. In the past month the price decreased by -4.23%. In the past year, price decreased by -79.71%.
AGTC Latest News, Press Relases and Analysis
AGTC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25.15 | 419.91B | ||
| AMGN | AMGEN INC | 15.79 | 185.92B | ||
| GILD | GILEAD SCIENCES INC | 15.53 | 157.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.32 | 112.70B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.59 | 74.36B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 879.92 | 58.82B | ||
| INSM | INSMED INC | N/A | 41.42B | ||
| NTRA | NATERA INC | N/A | 28.48B | ||
| BIIB | BIOGEN INC | 9.95 | 24.43B | ||
| INCY | INCYTE CORP | 16.67 | 20.90B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.7 | 21.13B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.39 | 14.67B |
Related stock screener links
About AGTC
Company Profile
Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The company is headquartered in Alachua, Florida and currently employs 102 full-time employees. The company went IPO on 2014-03-27. The firm uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM) and a optogenetics program, as well as a preclinical program in dry age-related macular degeneration (dAMD). The company has approximately one preclinical program in otology and two preclinical programs targeting central nervous system disorders (CN), including frontotemporal dementia and amyotrophic lateral sclerosis. Its optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.
Company Info
APPLIED GENETIC TECHNOLOGIES
Suite D, 11801 Research Drive
Alachua FLORIDA 32615 US
CEO: Susan B. Washer
Employees: 102
Phone: 13864622204.0
APPLIED GENETIC TECHNOLOGIES / AGTC FAQ
What does AGTC do?
Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The company is headquartered in Alachua, Florida and currently employs 102 full-time employees. The company went IPO on 2014-03-27. The firm uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM) and a optogenetics program, as well as a preclinical program in dry age-related macular degeneration (dAMD). The company has approximately one preclinical program in otology and two preclinical programs targeting central nervous system disorders (CN), including frontotemporal dementia and amyotrophic lateral sclerosis. Its optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.
What is the stock price of APPLIED GENETIC TECHNOLOGIES today?
The current stock price of AGTC is 0.3936 USD. The price increased by 1.23% in the last trading session.
What is the dividend status of APPLIED GENETIC TECHNOLOGIES?
AGTC does not pay a dividend.
What is the ChartMill rating of APPLIED GENETIC TECHNOLOGIES stock?
AGTC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting AGTC stock to perform?
10 analysts have analysed AGTC and the average price target is 0.37 USD. This implies a price decrease of -6.71% is expected in the next year compared to the current price of 0.3936.
What is the market capitalization of AGTC stock?
APPLIED GENETIC TECHNOLOGIES (AGTC) has a market capitalization of 26.62M USD. This makes AGTC a Nano Cap stock.
AGTC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AGTC. When comparing the yearly performance of all stocks, AGTC is a bad performer in the overall market: 83.06% of all stocks are doing better.
AGTC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AGTC. Both the profitability and financial health of AGTC have multiple concerns.
AGTC Financial Highlights
Over the last trailing twelve months AGTC reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS increased by 15.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.5% | ||
| ROE | N/A | ||
| Debt/Equity | 0.39 |
AGTC Forecast & Estimates
10 analysts have analysed AGTC and the average price target is 0.37 USD. This implies a price decrease of -6.71% is expected in the next year compared to the current price of 0.3936.